The company will move 2,700 employees from around the region to Cambridge Crossing.
The Boston, MA area has been recognized as a center for biotech for some time now. The Cambridge Crossing (previously North Point) development located on the Cambridge–Somerville line in East Cambridge is rapidly becoming an important biotech hub within the region. Most recently French drug-maker Sanofi announced that it will be consolidating its activities in two buildings encompassing 900,000 square feet at the development site. The deal is the largest single lease deal in the city’s history.
The Cambridge Crossing development covers 45 acres in total. In addition to Sanofi, other residents will include the North American headquarters of Royal Philips and precision medicine biotech company Goldfinch Bio.
Sanofi will move approximately 2,700 employees from around the region to the site once it is completed, which is expected to be some time in 2021. Both administrative and R&D work will be performed there. One of the main reasons for choosing the location was the ability to work closely with others in the biopharmaceutical industry. “Our new Sanofi site will further anchor us in this unique ecosystem of innovators for years to come,” said Sanofi Genzyme’s Executive Vice President Bill Sibold.
